½ÃÀ庸°í¼­
»óǰÄÚµå
1316573

µ¿¹°¿ë ¹é½Å ½ÃÀå : Á¦Ç° À¯Çüº°(¾àµ¶È­ »ý¹é½Å, DNA ¹é½Å, ºÒȰȭ ¹é½Å), µ¿¹° À¯Çüº°(¼ö»êµ¿¹°, ¹Ý·Áµ¿¹°, °¡±Ý·ù) - ¼¼°è ¿¹Ãø(2023-2030³â)

Animal Vaccines Market by Product (Attenuated Live Vaccines, DNA Vaccines, Inactivated Vaccines), Animal Type (Aqua, Companion, Poultry) - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 185 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µ¿¹°¿ë ¹é½Å ¼¼°è ½ÃÀåÀº 2023³â¿¡ 163¾ï 9,000¸¸ ´Þ·¯, CAGR 8.32%·Î »ó´çÇÑ ¼ºÀåÀÌ ¿¹ÃøµÇ¸ç, 2030³â¿¡´Â 287¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¼¼°èÀÇ µ¿¹°¿ë ¹é½Å ½ÃÀåÀ» Æò°¡Çϱâ À§Çؼ­ ÇʼöÀûÀÔ´Ï´Ù. »ç¾÷ Àü·«°ú Á¦Ç° ¸¸Á·µµÀÇ ÁÖ¿ä ÁöÇ¥¸¦ Á¶»çÇÏ¿© º¥´õÀÇ Á¾ÇÕÀûÀÎ Æò°¡¸¦ Á¦°øÇϰí, »ç¿ëÀڴ ƯÁ¤ ¿ä±¸¿¡ ±â¹ÝÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ÀÌ °í±Þ ºÐ¼®À» ÅëÇØ º¥´õ´Â ¼º°ø Á¤µµ°¡ ´Ù¸¥ 4°³ »óÇÑÀ¸·Î Á¤¸®µË´Ï´Ù : Forefront(F), Pathfinder(P), Niche(N), Vital(V)ÀÔ´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼®

½ÃÀå Á¡À¯À² ºÐ¼®¿¡¼­´Â ƯÁ¤ ½ÃÀå ¿µ¿ª¿¡¼­ º¥´õÀÇ ÇöȲÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ´Â ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ÀüüÀûÀÎ ¸ÅÃâ, °í°´ ±â¹Ý, ±âŸ ÁÖ¿ä ÁöÇ¥¿¡ ´ëÇÑ º¥´õÀÇ ±â¿©µµ¸¦ ºñ±³ÇÏ¿© ±â¾÷ÀÌ ½ÃÀå Á¡À¯À²À» ³õ°í °æÀïÇÒ ¶§ ÀÚ»ç ½ÇÀû°ú Á÷¸éÇϰí ÀÖ´Â »óȲÀ» ´õ ±í°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ ºÐ¼®¿¡¼­´Â Á¶»çÇÑ ±âÁØ ¿¬µµ¿¡¼­ ƯÁ¤ ºÎ¹®ÀÇ °æÀï Á¤µµ, ÃàÀû, ´ÜÆíÈ­ÀÇ ¿ìÀ§¼º, ÇÕº´ÀÇ Æ¯Â¡¿¡ ´ëÇØ¼­µµ ÆÄ¾ÇÇϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ´ÙÀ½ »çÇ׿¡ °üÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù:

1. ½ÃÀå ħÅõµµ : ÁÖ¿ä ±â¾÷ÀÌ Á¦°øÇÏ´Â ½ÃÀå¿¡ °üÇÑ Á¾ÇÕÀûÀÎ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

2. ½ÃÀå ¹ßÀü : À¯¸®ÇÑ ½ÅÈï ½ÃÀå¿¡ °üÇÑ »ó¼¼ Á¤º¸¸¦ Á¦°øÇϰí, ½ÃÀå ¼º¼÷ ºÎ¹®ÀÇ Ä§Åõµµ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ½ÅÁ¦Ç° Ãâ½Ã, ¹Ì°³¹ß Áö¿ª, ÃÖ±ÙÀÇ °³¹ß, ÅõÀÚ¿¡ °üÇÑ »ó¼¼ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

4. ½ÃÀå µ¿Çâ : COVID-19, ·¯½Ã¾Æ ¿ìÅ©¶óÀ̳ª ºÐÀï, °íÀÎÇ÷¹À̼ÇÀÇ ´©Àû ¿µÇâÀ» Á¾ÇÕÀûÀ¸·Î ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

5. °æÀï Æò°¡¿Í Á¤º¸ : ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À², Àü·«, Á¦Ç°, ÀÎÁõ, ±ÔÁ¦ »óȲ, ƯÇã »óȲ, Á¦Á¶´É·ÂÀ» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÕ´Ï´Ù.

6. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, ȹ±âÀûÀÎ Á¦Ç° °³¹ß¿¡ °üÇÑ ÁöÀû ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ´ÙÀ½°ú °°Àº Áú¹®¿¡ ´äº¯ÇÕ´Ï´Ù:

1. µ¿¹°¿ë ¹é½Å ¼¼°è ½ÃÀå ±Ô¸ð ¹× ¿¹ÃøÀº?

2. ¿¹Ãø±â°£ Áß ¼¼°èÀÇ µ¿¹°¿ë ¹é½Å ½ÃÀåÀ» Çü¼ºÇÏ´Â COVID-19ÀÇ ÀúÇØ¿äÀΰú ¿µÇâÀº?

3. µ¿¹°¿ë ¹é½Å ½ÃÀå¿¡¼­ ¿¹Ãø±â°£ Áß ÅõÀÚÇØ¾ß ÇÒ Á¦Ç°/ºÎ¹®/¾ÖÇø®ÄÉÀ̼Ç/ºÐ¾ß´Â?

4. µ¿¹°¿ë ¹é½Å ¼¼°è ½ÃÀåÀÇ °æÀï Àü·«Àº?

5. µ¿¹°¿ë ¹é½Å ¼¼°è ½ÃÀåÀÇ ±â¼ú µ¿Çâ°ú ±ÔÁ¦ ü°è´Â?

6. µ¿¹°¿ë ¹é½Å ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²Àº?

7. µ¿¹°¿ë ¹é½Å ¼¼°è ½ÃÀåÀ¸·ÎÀÇ ÁøÃâ¿¡´Â ¾î¶°ÇÑ Çüųª Àü·«ÀûÀΠȰµ¿ÀÌ ÀûÇÕÇÏ´Ù°í »ý°¢µÇ´Â°¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå µ¿Çâ
  • COVID-19ÀÇ ´©Àû ¿µÇâ
  • ·¯½Ã¾Æ ¿ìÅ©¶óÀ̳ª ºÐÀïÀÇ ´©Àû ¿µÇâ
  • °íÀÎÇ÷¹À̼ÇÀÇ ´©Àû ¿µÇâ
  • Porter's Five Forces ºÐ¼®
  • ¹ë·ùüÀΰú Áß¿ä °æ·Î ºÐ¼®
  • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
  • °í°´ Ä¿½ºÅ͸¶ÀÌÁî

Á¦6Àå µ¿¹°¿ë ¹é½Å ½ÃÀå : Á¦Ç°º°

  • ¾àµ¶È­ »ý¹é½Å
  • DNA ¹é½Å
  • ºÒȰȭ ¹é½Å
  • ÀçÁ¶ÇÕ ¹é½Å
  • ¾Æ´ÜÀ§ ¹é½Å

Á¦7Àå µ¿¹°¿ë ¹é½Å ½ÃÀå µ¿¹° Á¾·ùº°

  • ¾ÆÄí¾Æ
    • ¿¡·Î¸ð³ª½º
    • ·»»ç ±¸±ÕÁõ
    • ºñºê¸®¿À
  • ¹Ý·Á
    • °³°ú
      • °³Æ÷Áø
      • µð½ºÅÛÆÛ
      • ÄË³Ú ÄÚÇÁ
      • ¶óÀÓº´
      • ÆÄº¸¹ÙÀÌ·¯½º
      • ±¤°ßº´ °³
    • °í¾çÀ̰ú µ¿¹°
      • Ä®¸®½Ã¹ÙÀÌ·¯½º
      • Äڷγª¹ÙÀÌ·¯½º °í¾çÀÌ
      • ¹ü¹éÇ÷±¸ °¨¼ÒÁõ
      • °í¾çÀÌ ±¤°ßº´
      • ÄÚ±â°ü¿°
  • °¡±Ý
    • Á¶·ùÀÎÇ÷翣ÀÚ
    • °¨¿°¼º ±â°üÁö¿°
    • ¸¶·ºÅ©º´
    • ´ºÄ³½½º´
    • »ì¸ð³Ú¶ó±Õ
  • ¹ÝÃßµ¿¹°
    • Äڷγª¹ÙÀÌ·¯½º ¹ÝÃßµ¿¹°
    • ´ëÀå±Õ
    • ±¸Á¦¿ª(±¸Á¦¿ª)
    • ¿ïÅüºÒÅü ÇÑ ÇǺÎ
    • ·ÎŸ¹ÙÀÌ·¯½º

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ µ¿¹°¿ë ¹é½Å ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µ¿¹°¿ë ¹é½Å ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ µ¿¹°¿ë ¹é½Å ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦11Àå °æÀï »óȲ

  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • ½ÃÀå Á¡À¯À² ºÐ¼® : ÁÖ¿ä ±â¾÷º°
  • °æÀï ½Ã³ª¸®¿À ºÐ¼® : ÁÖ¿ä ±â¾÷º°

Á¦12Àå °ÔÀç ±â¾÷ ¸®½ºÆ®

Á¦13Àå ºÎ·Ï

  • ³íÀÇ °¡À̵å
  • ¶óÀ̼±½º¿Í °¡°Ý¿¡ ´ëÇØ
KSM 23.09.21

The Global Animal Vaccines Market is forecasted to grow significantly, with a projected USD 16.39 billion in 2023 at a CAGR of 8.32% and expected to reach a staggering USD 28.72 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Animal Vaccines Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Animal Vaccines Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Attenuated Live Vaccines, DNA Vaccines, Inactivated Vaccines, Recombinant Vaccines, and Subunit Vaccines. The Attenuated Live Vaccines commanded largest market share of 38.46% in 2022, followed by Inactivated Vaccines.

Based on Animal Type, market is studied across Aqua, Companion, Poultry, and Ruminants. The Aqua is further studied across Aeromonas, Streptococcosis, and Vibrio. The Companion is further studied across Canine and Feline. The Canine is further studied across Canine Herpes, Distemper, Kennel Cough, Lyme Disease, Parvovirus, and Rabies Canine. The Feline is further studied across Calicivirus, Coronavirus Feline, Panleukopenia, Rabies Feline, and Rhinotracheitis. The Poultry is further studied across Avian Influenza, Infectious Bronchitis, Marek's Disease, Newcastle Disease, and Salmonella. The Ruminants is further studied across Coronavirus Ruminants, E. Coli, Foot & mouth disease (FMD), Lumpy skin, and Rotavirus. The Companion commanded largest market share of 46.00% in 2022, followed by Ruminants.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 39.10% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Animal Vaccines Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Animal Vaccines Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Animal Vaccines Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Animal Vaccines Market?

4. What is the competitive strategic window for opportunities in the Global Animal Vaccines Market?

5. What are the technology trends and regulatory frameworks in the Global Animal Vaccines Market?

6. What is the market share of the leading vendors in the Global Animal Vaccines Market?

7. What modes and strategic moves are considered suitable for entering the Global Animal Vaccines Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Animal Vaccines Market, by Product, 2022 vs 2030
  • 4.3. Animal Vaccines Market, by Animal Type, 2022 vs 2030
  • 4.4. Animal Vaccines Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Livestock Population
      • 5.1.1.2. Rising Animal Husbandry along with Commercialization of Animal Products
      • 5.1.1.3. Increasing Incidences of Zoonotic Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Supply End Costs are Relatively High, with Poorer Capital Returns than Human Vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Shift from Live Attenuated Vaccines to DNA Vaccines
      • 5.1.3.2. Continuous Technological Advancements in Vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse Impacts of Vaccines
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Animal Vaccines Market, by Product

  • 6.1. Introduction
  • 6.2. Attenuated Live Vaccines
  • 6.3. DNA Vaccines
  • 6.4. Inactivated Vaccines
  • 6.5. Recombinant Vaccines
  • 6.6. Subunit Vaccines

7. Animal Vaccines Market, by Animal Type

  • 7.1. Introduction
  • 7.2. Aqua
    • 7.2.1. Aeromonas
    • 7.2.2. Streptococcosis
    • 7.2.3. Vibrio
  • 7.3. Companion
    • 7.3.1. Canine
      • 7.3.1.1. Canine Herpes
      • 7.3.1.2. Distemper
      • 7.3.1.3. Kennel Cough
      • 7.3.1.4. Lyme Disease
      • 7.3.1.5. Parvovirus
      • 7.3.1.6. Rabies Canine
    • 7.3.2. Feline
      • 7.3.2.1. Calicivirus
      • 7.3.2.2. Coronavirus Feline
      • 7.3.2.3. Panleukopenia
      • 7.3.2.4. Rabies Feline
      • 7.3.2.5. Rhinotracheitis
  • 7.4. Poultry
    • 7.4.1. Avian Influenza
    • 7.4.2. Infectious Bronchitis
    • 7.4.3. Marek's Disease
    • 7.4.4. Newcastle Disease
    • 7.4.5. Salmonella
  • 7.5. Ruminants
    • 7.5.1. Coronavirus Ruminants
    • 7.5.2. E. Coli
    • 7.5.3. Foot & mouth disease (FMD)
    • 7.5.4. Lumpy skin
    • 7.5.5. Rotavirus

8. Americas Animal Vaccines Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Animal Vaccines Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Animal Vaccines Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦